Furthermore, neutrophils expressing PD-L1 were linked to a poor prognosis in patients with advanced melanoma and are thought to be a novel biomarker in stage IV melanoma patients receiving anti-PD-1 immunotherapy [292]. This evidence concerns the gene CD274 and melanoma.